The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
July 10th 2025
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.
Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.
Watch
Real-World Data, Real-Time Decisions: AI at the Front Lines of Oncology
May 2nd 2025Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.
Watch
AACR 2025: Liposomal Annamycin May Enhance Chemotherapy Efficacy Across Hematologic and Solid Tumors
May 1st 2025Liposomal annamycin demonstrates broad synergistic activity with multiple FDA-approved chemotherapies across hematologic and solid tumors in preclinical models, offering a promising and safer combination strategy for resistant and high-risk cancers.
Read More
Precision Oncology in Focus: ctDNA's Role in Colon Cancer Management
April 30th 2025Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.
Watch
The phase 2 ROME trial demonstrated that combining tissue and liquid biopsies to guide tailored therapy in advanced solid tumors significantly improves survival outcomes compared to standard of care or single-biopsy approaches, highlighting the value of dual profiling in precision oncology.
Read More
AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML
April 27th 2025Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Read More